BIOAGE LABS INC (BIOA) Stock Price, Quote, News and Overview
NASDAQ:BIOA - Nasdaq - US09077V1008 - Currency: USD
BIOA Quote, Performance and Key Statistics
4.5
+0.1 (+2.27%)
The current stock price of BIOA is 4.5 USD. In the past month the price decreased by -15.09%.
BIOA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About BIOA
Company Profile
BIOAGE Labs Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Richmond California, California. The company went IPO on 2024-09-26. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. The company has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. The company is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
Company Info
BIOAGE LABS INC
1445A South 50Th Street
Richmond California CALIFORNIA H3B 4W8 US
CEO: Fabrice Orecchioni
Employees: 58
Company Website: https://bioagelabs.com
Phone: 15108061445
BIOAGE LABS INC / BIOA FAQ
What is the stock price of BIOAGE LABS INC today?
The current stock price of BIOA is 4.5 USD. The price increased by 2.27% in the last trading session.
What is the ticker symbol for BIOAGE LABS INC stock?
The exchange symbol of BIOAGE LABS INC is BIOA and it is listed on the Nasdaq exchange.
On which exchange is BIOA stock listed?
BIOA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOAGE LABS INC stock?
8 analysts have analysed BIOA and the average price target is 6.46 USD. This implies a price increase of 43.55% is expected in the next year compared to the current price of 4.5. Check the BIOAGE LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOAGE LABS INC worth?
BIOAGE LABS INC (BIOA) has a market capitalization of 161.32M USD. This makes BIOA a Micro Cap stock.
How many employees does BIOAGE LABS INC have?
BIOAGE LABS INC (BIOA) currently has 58 employees.
What are the support and resistance levels for BIOAGE LABS INC (BIOA) stock?
BIOAGE LABS INC (BIOA) has a support level at 4.27 and a resistance level at 4.67. Check the full technical report for a detailed analysis of BIOA support and resistance levels.
Should I buy BIOAGE LABS INC (BIOA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BIOA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BIOA, evaluating the profitability, health, valuation and growth aspects
- BIOAGE LABS INC (BIOA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOAGE LABS INC (BIOA) Sales and EPS estimates to see what analysts future expectations are.
- BIOAGE LABS INC (BIOA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOAGE LABS INC (BIOA) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOAGE LABS INC (BIOA) Stock Chart to make your own analysis
- BIOAGE LABS INC (BIOA) Latest news and press-releases to stay up to date.
Does BIOAGE LABS INC (BIOA) stock pay dividends?
BIOA does not pay a dividend.
What is the Price/Earnings (PE) ratio of BIOAGE LABS INC (BIOA)?
BIOAGE LABS INC (BIOA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.87).
What is the Short Interest ratio of BIOAGE LABS INC (BIOA) stock?
The outstanding short interest for BIOAGE LABS INC (BIOA) is 5.29% of its float. Check the ownership tab for more information on the BIOA short interest.
BIOA Technical Analysis
BIOA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BIOA. The financial health of BIOA is average, but there are quite some concerns on its profitability.
BIOA Financial Highlights
Over the last trailing twelve months BIOA reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS decreased by -60.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.93% | ||
| ROE | -20.35% | ||
| Debt/Equity | 0.01 |
BIOA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 45% to BIOA. The Buy consensus is the average rating of analysts ratings from 8 analysts.